[1]侯为洁 龚艳君.心脏磁共振在心脏淀粉样变性中的应用进展[J].心血管病学进展,2023,(9):796.[doi:10.16806/j.cnki.issn.1004-3934.2023.09.007]
　HOU Weijie,GONG Yanjun.Application of Cardiac Magnetic Resonance in Cardiac Amyloidosis[J].Advances in Cardiovascular Diseases,2023,(9):796.[doi:10.16806/j.cnki.issn.1004-3934.2023.09.007]
点击复制

心脏磁共振在心脏淀粉样变性中的应用进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2023年9期
页码:
796
栏目:
综述
出版日期:
2023-09-25

文章信息/Info

Title:
Application of Cardiac Magnetic Resonance in Cardiac Amyloidosis
作者:
侯为洁 龚艳君
(北京大学第一医院心内科,北京 100034)
Author(s):
HOU Weijie; GONG Yanjun
(Department of Cardiology,Peking University First Hospital,Beijing 100034,China)
关键词:
心脏磁共振; 心脏淀粉样变性; 心肌延迟强化;  Native T1; 细胞外间质容积;  T2 mapping; 心脏磁共振特征跟踪; 弥散张量成像
Keywords:
Cardiac magnetic resonance; Cardiac amyloidosis; Late gadolinium enhancement; Native T1; Extracellular volume; T2 mapping; Cardiac magnetic resonance feature tracking; Diffusion tensor imaging
DOI:
10.16806/j.cnki.issn.1004-3934.2023.09.007
摘要:
心脏淀粉样变性（CA）是指大量淀粉样纤维沉积于心肌细胞外间质，影响心脏结构与功能的一种严重疾病，随着病程进展，最终发展为严重的难治性心力衰竭。CA发病率低，目前诊断不足，且与肥厚型心肌病、高血压心脏病、主动脉瓣狭窄等引起心肌肥厚的疾病难以鉴别。心脏磁共振具有无创、软组织分辨率高、无电离辐射等优势，其中心肌延迟强化、T1 mapping、细胞外体积、T2 mapping、心脏磁共振特征跟踪以及弥散张量成像在CA的临床诊断、疾病分层和预后评估中有重要作用。现就心脏磁共振在CA的应用进展做一综述。
Abstract:
Cardiac amyloidosis(CA) is a serious disease in which a large number of amyloid fibers are deposited in the extracellular matrix of the myocardium,affecting the structure and function of the heart. With the progression of the disease,it eventually develops into severe refractory heart failure. The incidence rate of CA is low. At present,the diagnosis is insufficient,and it is difficult to distinguish CA from hypertrophic cardiomyopathy,hypertensive heart disease,aortic valve stenosis and other diseases that cause cardiac hypertrophy. Because of its non-invasive,high soft tissue resolution,non-radiation and other advantages,cardiac magnetic resonance such as late gadolinium enhancement,T1 mapping,extracellular volume,T2 mapping,cardiac magnetic resonance feature tracking and diffusion tensor imaging play an important role in the clinical diagnosis,disease stratification and prognosis evaluation of CA. This article will review the application progress of cardiac magnetic resonance in CA

参考文献/References:

[1] Flodrova P,Flodr P,Pika T,et al. Cardiac amyloidosis:from clinical suspicion to morphological diagnosis[J]. Pathology,2018,50(3):261-268.

[2] Dorbala S,Ando Y,Bokhari S,et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis:part 1 of 2-evidence base and standardized methods of imaging[J]. J Nucl Cardiol,2019,26(6):2065-2123.

[3] 田庄,李剑,吴炜,等. 遗传性转甲状腺素蛋白淀粉样变性心肌病的临床特点[J]. 中国介入心脏病学杂志,2015,23(5):260-264.

[4] Yilmaz A,Bauersachs J,Bengel F,et al. Diagnosis and treatment of cardiac amyloidosis:position statement of the German Cardiac Society(DGK)[J]. Clin Res Cardiol,2021,110(4):479-506.

[5] Saad JM,Ahmed AI,Han Y,et al. Cardiovascular magnetic resonance for suspected cardiac amyloidosis:where are we now?[J]. Heart Fail Rev,2022 ,27(5):1543-1548.

[6] Zhao L,Tian Z,Fang Q. Diagnostic accuracy of cardiovascular magnetic resonance for patients with suspected cardiac amyloidosis:a systematic review and meta-analysis [J]. BMC Cardiovasc Disord,2016 ,16:129

[7] Baggiano A,Boldrini M,Martinez-Naharro A,et al. Noncontrast magnetic resonance for the diagnosis of cardiac amyloidosis[J]. JACC Cardiovasc Imaging,2020,13(1 Pt 1):69-80.

[8] Messroghli DR,Moon JC,Ferreira VM,et al. Clinical recommendations for cardiovascular magnetic resonance mapping of T1,T2,T2* and extracellular volume:a consensus statement by the Society for Cardiovascular Magnetic Resonance(SCMR) endorsed by the European Association for Cardiovascular Imaging(EACVI) [J]. J Cardiovasc Magn Reson,2017,19(1):75.

[9] Wang TKM,Brizneda MV,Kwon DH,et al. Reference ranges,diagnostic and prognostic utility of native T1 mapping and extracellular volume for cardiac amyloidosis:a meta-analysis[J]. J Magn Reson Imaging,2021,53(5):1458-1468.

[10] Martinez-Naharro A,Abdel-Gadir A,Treibel TA,et al. CMR-verified regression of cardiac AL amyloid after chemotherapy[J]. JACC Cardiovasc Imaging,2018,11(1):152-154.

[11] Ridouani F,Damy T,Tacher V,et al. Myocardial native T2 measurement to differentiate light-chain and transthyretin cardiac amyloidosis and assess prognosis[J]. J Cardiovasc Magn Reson,2018,20(1):58.

[12] Korthals D,Chatzantonis G,Bietenbeck M,et al. CMR-based T1-mapping offers superior diagnostic value compared to longitudinal strain-based assessment of relative apical sparing in cardiac amyloidosis[J]. Sci Rep,2021,11(1):15521.

[13] Gotschy A,von Deuster C,van Gorkum RJH,et al. Characterizing cardiac involvement in amyloidosis using cardiovascular magnetic resonance diffusion tensor imaging[J]. J Cardiovasc Magn Reson,2019,21(1):56.

[14] 邓炜,李小虎, 心脏磁共振指纹技术研究进展[J]. 国际医学放射学杂志,2022,45(2):189-191,204.

[15] Eck BL,Seiberlich N,Flamm SD,et al. Characterization of cardiac amyloidosis using cardiac magnetic resonance fingerprinting[J]. Int J Cardiol,2022,351:107-110.

[16] Li X,Huang S,Han P,et al. Nonenhanced chemical exchange saturation transfer cardiac magnetic resonance imaging in patients with amyloid light-chain amyloidosis[J]. J Magn Reson Imaging,2022,55(2):567-576.

[17] Duran JR 3rd,Taffet G. Coronary microvascular dysfunction[J]. N Engl J Med,2007,356(22):2324-2325.

[18] Li R,Yang ZG,Wen LY,et al. Regional myocardial microvascular dysfunction in cardiac amyloid light-chain amyloidosis:assessment with 3T cardiovascular magnetic resonance[J]. J Cardiovasc Magn Reson,2016,18:16.

[19] Raina S,Lensing SY,Nairooz RS,et al. Prognostic value of late gadolinium enhancement CMR in systemic amyloidosis[J]. JACC Cardiovasc Imaging,2016,9(11):1267-1277.

[20] Fontana M,Banypersad SM,Treibel TA,et al. Native T1 mapping in transthyretin amyloidosis[J]. JACC Cardiovasc Imaging,2014,7(2):157-165.

[21] Fontana M,Banypersad SM,Treibel TA,et al. Differential myocyte responses in patients with cardiac transthyretin amyloidosis and light-chain amyloidosis:a cardiac MR imaging study[J]. Radiology,2015,277(2):388-397.

[22] Thomson LEJ. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis —Diagnostic value of a typical pattern of late gadolinium enhancement[J]. J Am Coll Cardiol,2008,51(10):1031-1032.

[23] Feng Y,Wu X,Zhang T,et al. Cardiac MR late gadolinium enhancement in evaluation on prognosis of patients with cardiac amyloidosis: meta-analysis[J]. Chin J Med Imaging Technol,2022,38(1):59-63.

[24] Li X,Li J,Lin L,et al. Left and right ventricular myocardial deformation and late gadolinium enhancement:incremental prognostic value in amyloid light-chain amyloidosis[J]. Cardiovasc Diagn Ther,2020,10(3):470-480.

[25] Banypersad SM,Fontana M,Maestrini V,et al. T1 mapping and survival in systemic light-chain amyloidosis[J]. Eur Heart J,2015,36(4):244-251.

[26] Martinez-Naharro A,Kotecha T,Norrington K,et al. Native T1 and extracellular volume in transthyretin amyloidosis[J]. JACC Cardiovasc Imaging,2019,12(5):810-819.

[27] Pan JA,Kerwin MJ,Salerno M. Native T1 mapping,extracellular volume mapping,and late gadolinium enhancement in cardiac amyloidosis[J]. JACC Cardiovasc Imaging,2020,13(6):1299-1310.

[28] Martinez-Naharro A,Patel R,Kotecha T,et al. Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment[J]. Eur Heart J,2022,43(45):4722-4735.

[29] Kotecha T,Martinez-Naharro A,Treibel TA,et al. Myocardial edema and prognosis in amyloidosis[J]. J Am Coll Cardiol,2018,71(25):2919-2931.

[30] Tan Z,Yang Y,Wu X,et al. Left atrial remodeling and the prognostic value of feature tracking derived left atrial strain in patients with light-chain amyloidosis:a cardiovascular magnetic resonance study[J]. Int J Cardiovasc Imaging,2022,38(7):1519-1532.

相似文献/References:

[1]张焰,饶莉.心脏淀粉样变性诊疗进展[J].心血管病学进展,2015,(5):527.[doi:10.3969/j.issn.1004-3934.2015.05.001]
　ZHANG Yan,RAO Li.Advances in Diagnosis and Treatment of Cardiac Amyloidosis[J].Advances in Cardiovascular Diseases,2015,(9):527.[doi:10.3969/j.issn.1004-3934.2015.05.001]
[2]郭彩艳 靳春荣.腺苷药物在心血管疾病诊治中的应用进展[J].心血管病学进展,2019,(7):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
　GUO CaiyanJIN Chunrong.Progress in the Application of Adenosine Drugs in the Diagnosis and Treatment of Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(9):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
[3]吴洋.左室心肌致密化不全的心脏磁共振诊断[J].心血管病学进展,2019,(5):673.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.004]
　WU Yang.Diagnosis of Left Ventricular Non-compaction Cardiomyopathy With Cardiac Magnetic Resonance Imaging[J].Advances in Cardiovascular Diseases,2019,(9):673.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.004]
[4]徐源蔚 陈玉成.心脏磁共振在检测自身免疫性风湿疾病心脏受累中的应用进展[J].心血管病学进展,2019,(5):676.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.005]
　XU Yuanwei,CHEN Yucheng.Advances in the Application of Cardiac Magnetic Resonance in Detecting Cardiac Involvement in Autoimmune Rheumatic Disease[J].Advances in Cardiovascular Diseases,2019,(9):676.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.005]
[5]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
　GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(9):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[6]冯泽豪 姜萌 卜军.心脏磁共振评价化疗所致心肌损伤的研究进展[J].心血管病学进展,2019,(5):667.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.003]
　FENG Zehao,JIANG Meng,PU Jun.Cardiovascular Magnetic Resonance for Detection of Myocardial Impairments Caused by Chemotherapy[J].Advances in Cardiovascular Diseases,2019,(9):667.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.003]
[7]金荣杰 徐勇 邓珏琳 沈明志.应用心脏磁共振评估前列地尔对ST段抬高型心肌梗死患者心肌灌注的影响[J].心血管病学进展,2020,(10):1096.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.023]
　JIN RongjieXU YongDENG JuelinSHEN Mingzhi.Effect of Alprostadil on Myocardial Perfusion of Patients with ST Segment Elevation Myocardial Infarction Directly Receiving Percutaneous Coronary Intervention Assessed with Cardiac Magnetic Resonance[J].Advances in Cardiovascular Diseases,2020,(9):1096.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.023]
[8]张宁 王嫱.心脏磁共振评估特发性炎症性肌病患者心脏受累的研究进展[J].心血管病学进展,2020,(11):1145.[doi:10.16806/j.cnki.issn.1004-3934.20.11.000]
　ZHANG Ning,WANG Qiang.Advances in Evaluating Cardiac Involvement in Idiopathic Inflammatory Myopathy by Cardiac Magnetic Resonance[J].Advances in Cardiovascular Diseases,2020,(9):1145.[doi:10.16806/j.cnki.issn.1004-3934.20.11.000]
[9]陈小玲 陈玉成.肺高压心肌纤维化磁共振评价及临床意义[J].心血管病学进展,2021,(2):135.[doi:10.16806/j.cnki.issn.1004-3934.2021.02.010]
　CHEN Xiaoling,CHEN Yucheng.Cardiac Magnetic Resonance Evaluation and the Clinical Value of Myocardial Fibrosis in Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2021,(9):135.[doi:10.16806/j.cnki.issn.1004-3934.2021.02.010]
[10]尹丽丹 蒲守芳 何娟 陈玉成.右心室评价方法及其临床应用[J].心血管病学进展,2021,(6):521.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.011]
　YIN Lidan,PU Shoufang,HE Juan,et al.The Methods to Evaluation of Right Ventricular and its Clinical Application[J].Advances in Cardiovascular Diseases,2021,(9):521.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.011]

更新日期/Last Update: 2023-10-17